enGene Holdings Inc. (S0N)
Market Open
XFRA XFRA Primary €
€
86.42M Market Cap
- P/E Ratio
- Div Yield
- Volume
-1.49 Eps
€
Previous Close Want to track S0N and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
S0N is not paying dividends to its shareholders.
The stock of the company had never split.
The company's stock is traded on one exchange.
enGene Holdings Inc. (S0N) FAQ
What is the stock price today?
The current price is €0.00.
On which exchange is it traded?
enGene Holdings Inc. is listed on XFRA.
What is its stock symbol?
The ticker symbol is S0N.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 86.42M.
Has enGene Holdings Inc. ever had a stock split?
No, there has never been a stock split.
enGene Holdings Inc. Profile
| Biotechnology Industry | Healthcare Sector | Dr. Alex Nichols Ph.D. CEO | XFRA Exchange | - ISIN |
| US Country | 31 Employees | - Last Dividend | - Last Split | 1 Nov 2023 IPO Date |
Overview
enGene Holdings Inc., through its pivotal subsidiary enGene, Inc., emerges in the biotechnological landscape as a significant clinical-stage entity predominantly focusing on the development of genetic medicines. This pioneering approach is notably characterized by the delivery of therapeutic solutions directly to mucosal tissues and various other organs, aiming to address a spectrum of diseases with groundbreaking precision and efficacy. Established in the year 2023, enGene Holdings Inc. has rapidly positioned itself as a beacon of innovation within the biotech industry. Its strategic base in Saint-Laurent, Canada, serves as a fertile ground for the company's research, development, and potential future expansions.
Products and Services
- EG-70 (detalimogene voraplasmid) - This flagship product represents enGene Holdings Inc.’s foray into the realm of non-viral immunotherapies, focused specifically on combatting non-muscle invasive bladder cancer (NMIBC). EG-70 is being developed with an aim to provide an effective treatment option for patients diagnosed with carcinoma-in-situ (Cis) who have not responded to traditional Bacillus Calmette-Guérin (BCG) therapy. By leveraging the unique delivery mechanisms and the innovative genetic engineering prowess of enGene, EG-70 stands as a testament to the company's commitment to providing novel and impactful solutions to those grappling with this challenging condition.
Contact Information
Address: 7171 Rue Frederick Banting, Saint-Laurent, QC, Canada, H4S 1Z9
Phone: 514 332 4888
Website: https://www.engene.com
